CN102065687A - 雷沙吉兰用于改善帕金森氏症 - Google Patents

雷沙吉兰用于改善帕金森氏症 Download PDF

Info

Publication number
CN102065687A
CN102065687A CN2009801230031A CN200980123003A CN102065687A CN 102065687 A CN102065687 A CN 102065687A CN 2009801230031 A CN2009801230031 A CN 2009801230031A CN 200980123003 A CN200980123003 A CN 200980123003A CN 102065687 A CN102065687 A CN 102065687A
Authority
CN
China
Prior art keywords
patient
disease
parkinson
rasagiline
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801230031A
Other languages
English (en)
Chinese (zh)
Inventor
鲁斯·利维
伊莱·伊亚尔
他玛·戈伦
希拉·奥伦
內姆·沙万里
孟德·尔韦斯
米瑞·本阿米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN102065687A publication Critical patent/CN102065687A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2009801230031A 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症 Pending CN102065687A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13193608P 2008-06-13 2008-06-13
US61/131,936 2008-06-13
US18972408P 2008-08-22 2008-08-22
US61/189,724 2008-08-22
PCT/US2009/003528 WO2009151625A1 (en) 2008-06-13 2009-06-12 Rasagiline for parkinson's disease modification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310714021.5A Division CN103893160A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症

Publications (1)

Publication Number Publication Date
CN102065687A true CN102065687A (zh) 2011-05-18

Family

ID=41415378

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801230031A Pending CN102065687A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症
CN201310714021.5A Pending CN103893160A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310714021.5A Pending CN103893160A (zh) 2008-06-13 2009-06-12 雷沙吉兰用于改善帕金森氏症

Country Status (13)

Country Link
US (2) US20090312436A1 (https=)
EP (2) EP2666356A1 (https=)
JP (3) JP2011522892A (https=)
CN (2) CN102065687A (https=)
AU (2) AU2009258151A1 (https=)
BR (1) BRPI0909894A2 (https=)
CA (1) CA2727022A1 (https=)
EA (1) EA201170018A1 (https=)
IL (1) IL209131A0 (https=)
MX (1) MX2010013766A (https=)
NZ (1) NZ589445A (https=)
WO (1) WO2009151625A1 (https=)
ZA (1) ZA201008484B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103857389A (zh) * 2011-10-10 2014-06-11 泰华制药工业有限公司 雷沙吉兰柠檬酰胺
CN116829145A (zh) * 2020-12-17 2023-09-29 巴尔-波特拉及康邦亚股份有限公司 早期特发性帕金森病的治疗方案

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20090181086A1 (en) * 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
MX2010013875A (es) 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US20120101168A1 (en) * 2010-10-26 2012-04-26 Eliezer Bahar Deuterium enriched rasagiline
CA2732440C (en) * 2011-02-23 2017-10-31 Universite Laval Cystamine analogues for the treatment of parkinson`s disease
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
EP3126527A4 (en) * 2014-04-01 2017-10-04 Teva Pharmaceutical Industries Ltd. Determination of single nucleotide polymorphisms useful to predict response for rasagiline
US10292947B2 (en) * 2016-03-26 2019-05-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions for N-propargylamine derivative
EP3606541A1 (en) * 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
AU2019427489B2 (en) * 2019-01-28 2025-03-13 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1062900A (zh) * 1991-01-02 1992-07-22 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体、其制法及含它的药物组合物
CN1191481A (zh) * 1995-05-22 1998-08-26 特瓦制药工业有限公司 N－炔丙基－1－氨基二氢化茚的r－对映体、其盐和组合物的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) * 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
EP1418834A4 (en) * 2001-07-20 2007-04-04 Sinai School Medicine METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
EP1466625A4 (en) * 2001-12-28 2007-07-18 Takeda Pharmaceutical PREVENTIVE / HEALING MEDICINE FOR BLADDER DISORDER
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
EP1954667B1 (en) * 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903903B (en) * 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
JP5356248B2 (ja) * 2006-12-14 2013-12-04 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンのタンニン酸塩
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090143388A1 (en) * 2007-08-29 2009-06-04 Mohanakumar Kochupurackal Para Treatment of brain disorders
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20090181086A1 (en) * 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1062900A (zh) * 1991-01-02 1992-07-22 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体、其制法及含它的药物组合物
CN1191481A (zh) * 1995-05-22 1998-08-26 特瓦制药工业有限公司 N－炔丙基－1－氨基二氢化茚的r－对映体、其盐和组合物的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
谢单丹: "抗帕金森病药 甲磺酸雷沙吉兰（rasgiline mesylate）", 《世界临床药物》 *
马建芳: "单胺氧化酶B型抑制剂治疗帕金森病的新进展", 《神经病学与神经康复学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103857389A (zh) * 2011-10-10 2014-06-11 泰华制药工业有限公司 雷沙吉兰柠檬酰胺
CN116829145A (zh) * 2020-12-17 2023-09-29 巴尔-波特拉及康邦亚股份有限公司 早期特发性帕金森病的治疗方案

Also Published As

Publication number Publication date
IL209131A0 (en) 2011-01-31
NZ589445A (en) 2013-06-28
JP2017081938A (ja) 2017-05-18
EP2296462A4 (en) 2011-06-15
ZA201008484B (en) 2012-05-30
CA2727022A1 (en) 2009-12-17
MX2010013766A (es) 2011-03-15
AU2009258151A1 (en) 2009-12-17
JP2011522892A (ja) 2011-08-04
JP2015096532A (ja) 2015-05-21
US20090312436A1 (en) 2009-12-17
EP2666356A1 (en) 2013-11-27
EP2296462A1 (en) 2011-03-23
AU2016259315A1 (en) 2016-12-01
US20140243418A1 (en) 2014-08-28
WO2009151625A1 (en) 2009-12-17
EA201170018A1 (ru) 2011-08-30
CN103893160A (zh) 2014-07-02
BRPI0909894A2 (pt) 2015-07-28

Similar Documents

Publication Publication Date Title
CN102065687A (zh) 雷沙吉兰用于改善帕金森氏症
Borobia et al. Inhaled methoxyflurane provides greater analgesia and faster onset of action versus standard analgesia in patients with trauma pain: InMEDIATE: a randomized controlled trial in emergency departments
Priebe et al. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem
Gironell et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor
Jankovic et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease
Klein et al. Symptom rating scale for assessing hyperthyroidism
Kim Association between objectively measured sleep quality and obesity in community-dwelling adults aged 80 years or older: a cross-sectional study
KR20170034452A (ko) 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법
Ibrahim et al. Muslim prayer movements as an alternative therapy in the treatment of erectile dysfunction: a preliminary study
KR20250034521A (ko) 실조증을 치료하기 위한 릴루졸 전구약물의 용도
Rodriguez-Larrad et al. Loss of benefits after cessation of exercise interventions in nursing home residents: randomized controlled trial follow-up
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
Higuchi et al. Does fear of falling relate to low physical function in frail elderly persons?: Associations of fear of falling, balance, and gait
WO2024216046A1 (en) Methods of treating anhedonia
Baddeley-White et al. Blood pressure-lowering efficacy of a 6-week multi-modal isometric exercise intervention
Ahmed et al. Prevalence and Associated factors of Temporomandibular Joint dysfunction among young adults in Karachi
Raj et al. Does Proprioception of knee improve after various forms of Training in Osteoarthritis of Knee?
Pedersen et al. Fractionated lower extremity response time performance in boys with and without ADHD
Mandelcorn et al. A preliminary study of the efficacy of ondansetron in the treatment of ataxia, poor balance and incoordination from brain injury
HK1192112A (en) Rasagiline for parkinson's disease modification
Pinvanichkul The effect of walking training with textured insole socks on standing balance and gait in older adults with a risk of falls
Dewan A review on diabetic neuropathy and development of sustained release tablet containing ‘Epalrestat’
Caciula et al. Exercise frequency and physical function in Parkinson’s disease
Roller et al. Disease state management: Parkinson's disease
Einerman et al. The Effects of Morning versus Evening Stretching Exercises in Hamstrings Flexibility Gains

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110518